Nomura issued a report stating that the revenue for the first half of the year was 3.8 billion yuan, up 41.2% year on year, driven by high growth in current business and Dongyao Pharmaceutical's contribution of 225 million yuan since April this year. In terms of profit margin, gross margin is estimated to have stabilized at 36% in the first half of the year, while operating margin dropped to 27.4% due to higher management expenses related to the acquisition of Dongyao Pharmaceutical, a decrease of 1.1 percent over the previous year; in addition to higher exchange losses, the net profit attributable to shareholders in the first half of the year is expected to be 747 million yuan. The bank lowered its target price from HK$87.73 to HK$82.6, maintained a “buy” rating, and lowered its profit for the 2026 fiscal year by 22.3% due to negative exchange rate effects and merger and acquisition costs associated with the acquisition of Dongyao Pharmaceutical.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.